rTMSDOULNEURO: Observational Study of the Analgesic Effect of Treatment With rTMS in Patients With Chronic Neuropathic Pain

Sponsor
University Hospital, Caen (Other)
Overall Status
Unknown status
CT.gov ID
NCT02506699
Collaborator
(none)
15
1
27
0.6

Study Details

Study Description

Brief Summary

For ten years, rTMS, repetitive transcranial magnetic stimulation of the motor cortex, has found its place in the treatment of drug-resistant neuropathic pain. Patients relieved by some sessions may thereafter receive a chronic invasive stimulation via electrodes implanted through a neurosurgical procedure. This is common practice at the University Hospital of Caen and in different CHU with the proper equipment rTMS. It seems permissible to provide in our center only a non-invasive technique for patients challenged with brain surgery, since according to the various meta-analyzes the analgesic efficacy of rTMS seems to be correlated to the repetition of sessions.

Assessment centers and the treatment of pain allow a multidimensional assessment, bio-psycho-social of patients in order to optimize their management and experience efficiently analgesics first- and second-line.

We propose a study evaluating the analgesic efficacy of rTMS, in relevant stimulation parameters reproduced according to a literature review, during 3 months after 5 active sessions separated by one week apart, in 15 patients with neuropathic pain chronic refractory to treatment of first and second line, followed by multidisciplinary center specializing in chronic pain Lower Normandy. The quality of life will also be assessed by validated scales, and the results will be compared to the literature data.

Condition or Disease Intervention/Treatment Phase
  • Other: analgesic effect of rTMS

Study Design

Study Type:
Observational
Anticipated Enrollment :
15 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observational Study of the Analgesic Effect of Treatment With rTMS in Patients Suffering From Chronic Neuropathic Pain Refractory to Conventional Treatment and Monitored and Evaluated in Consultation Multidisciplinary Chronic Pain in Lower Normandy
Study Start Date :
Jun 1, 2013
Anticipated Primary Completion Date :
Sep 1, 2015
Anticipated Study Completion Date :
Sep 1, 2015

Arms and Interventions

Arm Intervention/Treatment
analgesic effect of rTMS

Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.

Other: analgesic effect of rTMS

Outcome Measures

Primary Outcome Measures

  1. NPSI (Neuropathic Pain Symptom Inventory) [baseline and after 17 weeks]

    Analysis of analgesic efficacy: evolution of NPSI (Neuropathic Pain Symptom Inventory), validated scale in monitoring neuropathic pain, and VAS (visual analogue scale), to fill once a week over a period of 17 weeks, from one week before the first session of rTMS until three months after the last rTMS session.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient 18 to 70 years with:
  1. Pain lasting for more than six months;

  2. Monitoring in CETD in Normandy;

  3. Having had a bio-psycho-social assessment and have been the subject of a multidisciplinary discussions recorded in the medical record;

  4. Presenting unilateral neuropathic pain, central or peripheral origin:

  • may affect the face,

  • upper limb,

  • or hémicorps but including at least the upper limb;

  1. With neuropathic pain screening test positive (≥ DN4 4/10);

  2. etiology objectified by further examinations (MRI, scanner, or EMG, PES MEP);

  3. Resistant to usual treatments: less than 50% improvement compared to the initial pain (EN or EVA) in patients who received an effective dose for treatment of first and a second intention.

Exclusion Criteria:
  • Contraindications of rTMS:
  1. Brain implanted ferromagnetic material,

  2. Implanted neurostimulator (cortical and deep brain, spinal cord)

  3. Cochlear Implants

  4. Active epilepsy (seizures despite existence of a current treatment)

  5. Pacemakers

  6. Hearing loss or current taking ototoxic drugs (aminoglycosides, cisplatin)

  • Pregnancy, breastfeeding, lack of effective contraception for patients of childbearing age

  • Psychiatric illness decompensated

  • Cancer pain and post-chemotherapy

  • severe cognitive disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre d'évaluation et de traitement de la douleur (CETD) Caen France 14000

Sponsors and Collaborators

  • University Hospital, Caen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT02506699
Other Study ID Numbers:
  • 13-025
First Posted:
Jul 23, 2015
Last Update Posted:
Jul 23, 2015
Last Verified:
Jul 1, 2015
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 23, 2015